Citation Impact
Citing Papers
Suppression of Proximal T Cell Receptor Signaling and Lytic Function in CD8+ Tumor-Infiltrating T Cells
2007
High-throughput characterization of protein–protein interactions by reprogramming yeast mating
2017 StandoutNobel
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion
2010 StandoutNobel
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Untangling the ErbB signalling network
2001 Standout
HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice
2003
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
1998
Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.
1995
Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
2000
Systemic Targeting of CpG-ODN to the Tumor Microenvironment with Anti–neu-CpG Hybrid Molecule and T Regulatory Cell Depletion Induces Memory Responses in BALB-neuT Tolerant Mice
2008 StandoutNobel
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
2001
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
2000
HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer
1997
Treml4, an Ig Superfamily Member, Mediates Presentation of Several Antigens to T Cells In Vivo, Including Protective Immunity to HER2 Protein
2011 StandoutNobel
Immunosurveillance ofErbb2Carcinogenesis in Transgenic Mice Is Concealed by a Dominant Regulatory T-Cell Self-Tolerance
2006
Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity
1998
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
1998 Standout
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Naturally occurring B-cell responses to breast cancer
2003
Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma
2004
Human tumor antigens recognized by T-cells
1997
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma
1997
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Towards patient‐specific tumor antigen selection for vaccination
2002
Essential role of NAT1/p97/DAP5 in embryonic differentiation and the retinoic acid pathway
2000 StandoutNobel
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
2005 StandoutNobel
Engineered T cells: the promise and challenges of cancer immunotherapy
2016
Leukocytes in Mammary Development and Cancer
2010
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Human tumor antigens for cancer vaccine development
1999
Serological identification of breast cancer-related antigens from aSaccharomyces cerevisiae surface display library
2005
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
2002 Standout
Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
1997
Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes
1998 Standout
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
1997
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
1996 Standout
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
1996
Breast cancer–associated antigen, DF3/MUC1, induces apoptosis of activated human T cells
1996
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
2001
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
2017 Standout
In vivoblockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
1999 StandoutNobel
Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines
2002
Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers
1998
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
2004 Standout
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
1999 StandoutNobel
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Stimulation of the Glucocorticoid-Induced TNF Receptor Family-Related Receptor on CD8 T Cells Induces Protective and High-Avidity T Cell Responses to Tumor-Specific Antigens
2010 StandoutNobel
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
1995
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
2001 StandoutNobel
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
2008 StandoutNobel
Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer
2005 StandoutNobel
Characterization of a messenger RNA polynucleotide vaccine vector.
1995
Alphavirus-based expression vectors: strategies and applications.
1996 StandoutNobel
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity
2006 StandoutNobel
Human neoplasms elicit multiple specific immune responses in the autologous host.
1995
IL-2 Immunotoxin Therapy Modulates Tumor-Associated Regulatory T Cells and Leads to Lasting Immune-Mediated Rejection of Breast Cancers in neu-Transgenic Mice
2006
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells
2005 StandoutNobel
Role of HER2 gene overexpression in breast carcinoma
2000
Multiple pathways to tumor immunity and concomitant autoimmunity
2002
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response
2000 StandoutNobel
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
1995
Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
1995
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients
2005
Serological analysis of human tumor antigens: molecular definition and implications
1997
Cancer-induced Defective Cytotoxic T Lymphocyte Effector Function: Another Mechanism How Antigenic Tumors Escape Immune-mediated Killing
2000
Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis
2001
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
2005 StandoutNobel
Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity
2006 StandoutNobel
A sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expressionin vivo
1995
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
1999 StandoutNobel
Human tumor antigens recognized by T lymphocytes.
1996
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
2016
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Works of Ann Murphy being referenced
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
1994
In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
1994